Sanofi Genzyme
500 Kendall Street
Cambridge
Massachusetts
02142
United States
Tel: 617-252-7500
Fax: 617-252-7600
Website: https://www.sanofigenzyme.com/
About Sanofi Genzyme
About Genzyme
Genzyme is committed to discovering and delivering transformative therapies for patients with rare and special unmet medical needs, providing hope where there was none before.
Genzyme has pioneered the development and delivery of transformative therapies for over 30 years. Founded in 1981 in Boston, Massachusetts, Genzyme evolved from a tiny start-up with just a handful of employees to one of the world's leading biotech companies. Acquired by Sanofi in 2011, Genzyme now benefits from the reach and resources of one of the world’s largest pharmaceutical companies, with a shared commitment to improving the lives of patients.
Genzyme has long been known for our expertise in the class of rare genetic diseases known as lysosomal storage disorders (LSDs). LSDs remain the heart of our company today, but we have also expanded – through both in-house development and strategic acquisitions and partnerships – to other disease areas such as thyroid cancer and multiple sclerosis.
About Sanofi
Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets, and animal health. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
776 articles about Sanofi Genzyme
-
Alnylam and Sanofi Submit Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for Patisiran for the Treatment of Hereditary ATTR (hATTR) Amyloidosis
12/18/2017
Alnylam announced today the submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for patisiran.
-
Clinical trial dosing will resume around year-end 2017.
-
Sanofi Genzyme Release: Prince Edward Island Includes LEMTRADA (Alemtuzumab) On Provincial Drug Program For Eligible Patients
8/2/2017
-
Alnylam And Sanofi Genzyme Report Positive Results From Ongoing Phase II Open-Label Extension Study With Investigational Rnai Therapeutic Fitusiran In Patients With Hemophilia A And B With Or Without Inhibitors
7/10/2017
-
Alnylam And Sanofi Genzyme Initiate ATLAS Phase III Program With Investigational RNAi Therapeutic Fitusiran In Patients With Hemophilia A And B With Or Without Inhibitors
7/7/2017
-
Alnylam And Sanofi Genzyme To Present New Clinical Trial Results At The International Society Of Thrombosis And Haemostasis (ISTH) Congress
6/27/2017
-
Another Top Sanofi Genzyme Exec Jumps Ship
5/11/2017
-
Sanofi Genzyme Announces Approval Of Cerdelga (Eliglustat Capsules) By Health Canada For Rare Genetic Condition
5/1/2017
-
New Investigational Data On Six-Year Efficacy Of Sanofi Genzyme’s Lemtrada (Alemtuzumab) In Multiple Sclerosis Patients Who Experienced Relapse Between Treatment Courses To Be Presented At American Academy of Neurology
4/25/2017
-
New Data Suggest Positive Effects Of Sanofi Genzyme’s Aubagio (Teriflunomide) On Cortical Gray Matter Atrophy
4/25/2017
-
Rhythm Appoints Head Of Sanofi Genzyme, Dr. David Meeker, As Chairman Of Board Of Directors
4/11/2017
-
More Than 30 Presentations Of New Investigational Data From Sanofi Genzyme’s Multiple Sclerosis Franchise To Be Featured AtAAN
4/11/2017
-
Sanofi Genzyme Exec Exits to Become CMO of Flexion—Sanofi's Rumored Buyout Target
4/10/2017
-
Sanofi Genzyme Head to Leave After 23 Years on the Job, Replacement Named
4/6/2017
-
Sanofi Genzyme Extends Its Multiple Myeloma Journey Partners Program To Cities Nationwide To Help Improve Patient Outcomes Through Peer-To-Peer Education
3/22/2017
-
What’s That Thing On Top Of The Sanofi Genzyme Building Anyway?
3/14/2017
-
Sanofi Genzyme Release: Kevzara (Sarilumab) Now Available In Canada For The Treatment Of Adult Patients With Moderately To Severely Active Rheumatoid Arthritis
2/28/2017
-
Sanofi Genzyme Recognizes Rare Disease Day 2017 With Programs Of Events Around The World
2/28/2017
-
Sanofi Genzyme Announces Start Of Phase III Study Of Isatuximab For Relapsed And Refractory Multiple Myeloma
12/5/2016
-
Sanofi Genzyme Release: Nova Scotia Includes LEMTRADA (Alemtuzumab) On Provincial Drug Program For Eligible Patients
12/2/2016